Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 8/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28563540 | 0.74 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL30987223 | 0.74 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL9487343 | 0.70 | KDM4E (0.37) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL5814878 | 0.69 | CHRM2 (0.40) | MAPTKDM4EALDH1A1 | |
| SCHEMBL3144177 | 0.69 | RAB9A (0.46) | MAPTKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL7808907 | 0.68 | KDM4E (0.42) | MAPTKDM4EALDH1A1HSD17B10HTR1A | |
| SCHEMBL6964514 | 0.67 | KDM4E (0.52) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL2958656 | 0.67 | CA1 (0.36) | MAPTKDM4EALDH1A1HSD17B10EPHX2 | |
| SCHEMBL5567669 | 0.67 | KDM4E (0.36) | MAPTKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL9867507 | 0.67 | KDM4E (0.39) | MAPTKDM4EALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4484703-B2 | — | — | 2010-06-16 | — | — | JP | claimed |
| US-20070093478-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | US | claimed |
| JP-2006504658-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1527050-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-04 | — | — | EP | claimed |
| WO-2004011436-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-05 | — | — | WO | claimed |
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | MAPT 252/4885KDM4E 3278/4885ALDH1A1 611/4885 |
| US-20070093478-A1 | Novel mycobacterial inhibitors | NQO2, NAT1, HRH1 | MAPT 854/4885KDM4E 4559/4885ALDH1A1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.